Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA.
Remon J, Caramella C, Jovelet C, Lacroix L, Lawson A, Smalley S, Howarth K, Gale D, Green E, Plagnol V, Rosenfeld N, Planchard D, Bluthgen MV, Gazzah A, Pannet C, Nicotra C, Auclin E, Soria JC, Besse B.
Remon J, et al. Among authors: planchard d.
Ann Oncol. 2017 Apr 1;28(4):784-790. doi: 10.1093/annonc/mdx017.
Ann Oncol. 2017.
PMID: 28104619
Free article.
Clinical Trial.